# CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

> **NCT04906213** · PHASE2 · TERMINATED · sponsor: **Duke University** · enrollment: 20 (actual)

## Conditions studied

- Kidney Transplant; Complications
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Empagliflozin10Mg Tab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04906213
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-25
- **Primary completion:** 2026-01-22
- **Final completion:** 2026-01-22
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** The study closed per PI decision due to completion of the biopsy substudy and slow accrual
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04906213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04906213, "CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04906213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*